New investigational drug for newly-diagnosed MGMT unmethylated glioblastoma
- Trial ID:
- IRB-24-8483
- Tresa McGranahan, MD PhD
Inclusion Criteria
Patients must:
- Be a man or woman 18 years of age or older
Have no prior treatment for GBM, other than surgical resection or biopsy
Have normal blood pressure or adequately treated and controlled hypertension
Be able to undergo MRI brain with intravenous (IV) contrast
Exclusion Criteria
Patients must not:
- Have metastatic or predominant leptomeningeal disease
Have current active pneumonitis or any history of pneumonitis within 90 days of start of study
Have a history of another malignancy within 2 years
Additional Info
Study visits include health checks, tests, medication diaries and questionnaires. All study visits will be scheduled at Scripps Clinic Torrey Pines or Prebys Cancer Center in Hillcrest. Participants may continue to take the niraparib or TMZ as long as the cancer does not get worse or completion of 6 cycles of treatment (TMZ).More information can be found at clinicaltrials.gov using NCT06388733.
Contact Info:
- Clinical Research Services
- CRSLeadership@scrippshealth.org